14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today BPMC ranks #13879 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Blueprint Medicines Corporation Stock Forecast NASDAQ:BPMC

$94.25 (-4.32%)

Volume: 615k

Closed: Dec 03, 2021

Hollow Logo Score: -3.517

Blueprint Medicines Corporation Stock Forecast

$94.25 (-4.32%)

Volume: 615k

Closed: Dec 03, 2021

Score Hollow Logo -3.517
Which way will BPMC go? Request
Key Stats
P/E Ratio -13.49
Beta 1.29
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 14 and the stock is extremely oversold on RSI14, but some stocks may continue to fall despite the high chance of a correction up. The low RSI lowers the general risk and the stock should be considered if other technical requirements like liquidity and risk-reward are meet.

Red day on Friday for Blueprint Medicines Corporation
(Updated on Dec 03, 2021)


Sell candidate since 2021-12-03

The Blueprint Medicines Corporation stock price fell by -4.32% on the last day (Friday, 3rd Dec 2021) from $98.51 to $94.25. During the day the stock fluctuated 6.26% from a day low at $93.04 to a day high of $98.86. The price has fallen in 8 of the last 10 days and is down by -14.62% for this period. Volume has increased on the last day by 255 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 615 thousand shares were bought and sold for approximately $57.92 million.

The stock has broken the wide and weak rising short-term trend down. This signalizes a slower rate of rising, but may also be an early warning about a possible trend shift. Due to the trend being broken there will now be resistance at the bottom line of the trend at $100.99. A reaction back to this level may hold a second chance to get out before further falls.

Signals & Forecast

There are few to no technical positive signals at the moment. The Blueprint Medicines Corporation stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $98.34 and $106.90. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Thursday, November 11, 2021, and so far it has fallen -18.74%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.

Support, Risk & Stop-loss

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $5.82 between high and low, or 6.26%. For the last week, the stock has had a daily average volatility of 5.39%.

Blueprint Medicines Corporation is oversold on RSI14 (14). Some stocks may fall long and hard while being oversold on RSI, but stocks that are heavily oversold on RSI often pose good re-bounce chance and played well it can be a buy candidate.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Blueprint Medicines Corporation stock A Buy?

The Blueprint Medicines Corporation stock holds several negative signals and despite the positive trend, we believe Blueprint Medicines Corporation will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

Current score: -3.517

Predicted Opening Price for Blueprint Medicines Corporation of Monday, December 6, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price December 6, 2021 Current price
$95.38 $94.25 (Undervalued)
Sell Candidate Unchanged

Remember To Visit Our YouTube Channel

Analyst Ratings

On Nov 30, 2021 "JMP Securities" gave "$151.00" rating for BPMC. The price target was changed from $95.08 to 3.3%.

Volatility and Risk
Daily Average Volatility: 5.39 %
Overall Risk: Very High High Medium Low Very Low
Volatility
5.39 %
Daily Average Volatility
Overall Risk

Very High
High
Medium
Low
Very Low

Support & Resistance

Resistance: $102.52
Price: $94.25
No Support Found

BPMC Insider Trading Show all Trades

INSIDER POWER

0.590

Last 100 transactions
Buy: 154 833 | Sell: 262 515 (Shares)
Date Action Amount Person Type
Nov 16, 2021 Sell 600 Hurley Ariel Stock Option (Right to Buy)
Nov 16, 2021 Sell 650 Hurley Ariel Stock Option (Right to Buy)
Nov 16, 2021 Sell 700 Hurley Ariel Stock Option (Right to Buy)
Nov 16, 2021 Sell 1 950 Hurley Ariel Common Stock
Nov 16, 2021 Buy 600 Hurley Ariel Common Stock
Show all Insider Trades
INSIDER POWER

0.590

Last 100 transactions
Buy: 154 833 | Sell: 262 515 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 101.20 7.38 %
98.98 5.02 %
97.61 3.56 %
Current price: 94.25
Support 93.16 -1.16 %
91.79 -2.61 %
89.56 -4.97 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 113.33 20.24 %
106.00 12.47 %
102.52 8.77 %
Current price 94.25
Support 0 .
0 .
0 .

Click to get the best stock tips daily for free!

About Blueprint Medicines Corporation

Blueprint Medicines Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases. Its lead drug candidates include BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorder of the mast cells, and defined subsets of patie... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT